Cellectar Biosciences (CLRB) Net Cash Flow (2010 - 2025)
Cellectar Biosciences (CLRB) posted Net Cash Flow of $647624.0 for Q4 2025, down 57.2% sequentially from $1.5 million in Q3 2025, and up 105.9% YoY from $314531.7 in Q4 2024.
Cellectar Biosciences (CLRB) Net Cash Flow (2010 - 2025) Analysis & Trends
Cellectar Biosciences has reported Net Cash Flow for 16 years, with the latest figure at $647624.0 in Q4 2025.
- Quarterly Net Cash Flow rose 105.9% year-over-year to $647624.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.3 million (down 189.9% YoY) and the FY2025 annual result came in at -$10.1 million, down 173.54% from the prior year.
- Net Cash Flow eased to $647624.0 in Q4 2025 per CLRB's latest filing, from $1.5 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $30.5 million in Q1 2024 and troughed at -$14.2 million in Q2 2024.
- A 5-year average of -$2.8 million and a median of -$6.1 million in 2021 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2021 and 2024: Net Cash Flow sank 144.55% in 2021, then surged 524.1% in 2024.
- Over 5 years, Net Cash Flow stood at -$4.6 million in 2021, then tumbled by 62.25% to -$7.5 million in 2022, then decreased by 25.13% to -$9.4 million in 2023, then decreased by 16.49% to -$11.0 million in 2024, then jumped by 105.9% to $647624.0 in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $647624.0, $1.5 million, and -$5.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 225.59 Mn |
| 10 | Cellectar Biosciences | 6.76 Mn | 6.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 647,624.00 |
| Dec 31, 2025 | 647,624.00 |
| Sep 30, 2025 | 1.51 Mn |
| Sep 30, 2025 | 1.51 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Mar 31, 2025 | -9.38 Mn |
| Mar 31, 2025 | -9.38 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Sep 30, 2024 | 8.39 Mn |
| Sep 30, 2024 | 8.39 Mn |
| Jun 30, 2024 | -14.16 Mn |
| Jun 30, 2024 | -14.16 Mn |
| Mar 31, 2024 | 30.47 Mn |
| Mar 31, 2024 | 30.47 Mn |
| Dec 31, 2023 | -9.42 Mn |
| Dec 31, 2023 | -9.42 Mn |
| Sep 30, 2023 | 14.43 Mn |
| Sep 30, 2023 | 14.43 Mn |